INTRODUCTION
Hypertension is a prevalent condition that if left uncontrolled can increase cardiovascular morbidity and mortality as manifested by increased incidence of ischemic heart disease and stroke [1] . For many patients, achievement of blood pressure (BP) control requires escalation of monotherapy to combination therapy with agents from multiple pharmacological classes [2, 3] . Despite the recommendations of clinical practice guidelines, only 48.4% of patients have their hypertension controlled by treatment [4] .
The Blood Pressure Control in All Subgroups
With Hypertension (BP-CRUSH) study (ClinicalTrials.gov identifier: NCT00791258) evaluated improvement in BP goal achievement after patients who were uncontrolled on prior antihypertensive monotherapy were switched to a fixed-dose of amlodipine/olmesartan medoxomil (AML/OM), with or without hydrochlorothiazide (HCTZ), combination treatment regimen [5] . Fixed-dose combination therapy is one proven strategy to escalate therapy in patients who have hypertension uncontrolled by a single agent alone. In one study of 45 Canadian family practice sites, a simplified approach to hypertension treatment employing fixed-dose combination therapy was compared against treatment as usual, which resulted in significantly improved BP control of 64.7% versus 52.7%, respectively (P = 0.026) [6] . Fixeddose combination therapy also has the added benefit of improving adherence [7] and longterm savings for the healthcare system, despite potentially higher out-of-pocket costs [8] .
The purpose of this secondary analysis is to present the BP goal achievement rates, BP reductions, and safety findings of study patients in the primary BP-CRUSH study who did not achieve BP control with prior calcium channel blocker (CCB) or angiotensin II receptor blocker (ARB) monotherapy at baseline, and who were subsequently escalated to AML/OM ± HCTZ fixed-dose combination therapy.
MATERIALS AND METHODS

Study Design
The BP-CRUSH study was a 20-week, prospective, open-label, multicenter, phase 4 (3b in South Africa) study in 999 patients with hypertension.
Complete inclusion and exclusion criteria have been published previously [5] . Briefly, patients 18-80 years of age were eligible to enter the study if their mean seated cuff systolic BP (SeSBP) 
Efficacy Assessments
The primary efficacy endpoint was the cumulative proportion of patients achieving the SeSBP goal of <140 mmHg (or <130 mmHg in patients with diabetes) after 12 weeks of treatment. 
Safety Assessments
Safety variables measured included adverse events, laboratory parameters, vital signs, and physical examinations. Adverse events were collected and reported from the time of entry into the study for up to 14 days after the last dose of the study drug. An assessment of the severity of adverse events was made, as was a determination of causality with respect to study treatment.
Statistical Analysis
Demographics and baseline characteristics of the study population were summarized using 
RESULTS
Baseline Demographics
A total of 999 patients were enrolled into the primary study wherein 118 patients had uncontrolled BP on prior CCB monotherapy and 237 patients had uncontrolled BP on prior ARB monotherapy. Table 2 ARB group. Table 3 shows the most commonly reported drug-related TEAEs by titration dose and by total for each subgroup. The most frequently reported drug-related TEAEs were dizziness, peripheral edema, hypotension, nausea, fatigue, and muscle spasms. The most frequently reported drug-related TEAE in both the prior CCB and prior ARB groups was peripheral edema at a total rate of 4.2% and 6.8%, respectively.
Safety and Tolerability
The highest incidence of drug-related peripheral edema was observed at the maximum AML/OM 10/40 mg dose in both the prior CCB (2.0%) and prior ARB (5.0%) groups. When HCTZ 12.5 mg and 25 mg were added on to AML/OM, overall rates of drug-related peripheral edema decreased from 3.4% to 1.1% and from 5.9% to 1.1% in the prior CCB and prior ARB groups, respectively.
There were no adverse events leading to death in the BP-CRUSH study. 
